[go: up one dir, main page]

NO954568L - Fremgangsmåte for rekombinant fremstilling av biologisk aktive peptider - Google Patents

Fremgangsmåte for rekombinant fremstilling av biologisk aktive peptider

Info

Publication number
NO954568L
NO954568L NO954568A NO954568A NO954568L NO 954568 L NO954568 L NO 954568L NO 954568 A NO954568 A NO 954568A NO 954568 A NO954568 A NO 954568A NO 954568 L NO954568 L NO 954568L
Authority
NO
Norway
Prior art keywords
biologically active
recombinant production
active peptides
antigen
specific
Prior art date
Application number
NO954568A
Other languages
English (en)
Other versions
NO954568D0 (no
Inventor
Kimishige Ishizaka
Yun-Cai Liu
Toshifumi Mikayama
Original Assignee
Jolla Inst Allergy Immunolog
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Inst Allergy Immunolog, Kirin Brewery filed Critical Jolla Inst Allergy Immunolog
Publication of NO954568D0 publication Critical patent/NO954568D0/no
Publication of NO954568L publication Critical patent/NO954568L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Polypeptider, polynukleotider og fragmenter av disse, foruten monoklonale antistoffer til disse, tilveiebringes for antigen-spesifikk og antigen ikke-spesifikk glykosylerings- hemmende faktor, og en fremgangsmåte for rekombinant produksjon av biolgisk, aktive polypeptider fra et strukturelt gen som koder polypeptidet.
NO954568A 1993-05-14 1995-11-13 Fremgangsmåte for rekombinant fremstilling av biologisk aktive peptider NO954568L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6104193A 1993-05-14 1993-05-14
PCT/US1994/005354 WO1994026923A1 (en) 1993-05-14 1994-05-13 Method for recombinant production of biologically active polypeptides

Publications (2)

Publication Number Publication Date
NO954568D0 NO954568D0 (no) 1995-11-13
NO954568L true NO954568L (no) 1996-01-11

Family

ID=22033267

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954568A NO954568L (no) 1993-05-14 1995-11-13 Fremgangsmåte for rekombinant fremstilling av biologisk aktive peptider

Country Status (13)

Country Link
EP (1) EP0702725B1 (no)
JP (1) JP3578787B2 (no)
KR (1) KR960702868A (no)
CN (1) CN1126494A (no)
AT (1) ATE332392T1 (no)
AU (1) AU692450B2 (no)
CA (1) CA2162865A1 (no)
DE (1) DE69434782T2 (no)
FI (1) FI955463L (no)
HU (1) HU219807B (no)
NO (1) NO954568L (no)
NZ (1) NZ267254A (no)
WO (1) WO1994026923A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910427A (en) * 1995-06-22 1999-06-08 La Jolla Institute For Allergy And Immunology Antigen non-specific glycosylation inhibiting factor derivatives
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
AU784477B2 (en) * 1999-11-19 2006-04-13 Shire Human Genetic Therapies, Inc. Nucleic acid construct for optimized production of products
DE19957904A1 (de) * 1999-12-01 2001-06-07 Merck Patent Gmbh Insektengift-Allergene mit verminderter IgE-Reaktivität und Verfahren zu ihrer Herstellung
SG176303A1 (en) * 2009-06-10 2012-01-30 Stephen Sanig Res Inst Ltd Methods of generating cells exhibiting phenotypic plasticity
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0285405A1 (en) * 1987-03-31 1988-10-05 Schering Biotech Corporation Glycosylation inhibition factors
CA2103046A1 (en) * 1991-06-03 1992-12-04 Kimishige Ishizaka Suppressor t-cell hybridoma
WO1994026307A1 (en) * 1993-05-17 1994-11-24 The Picower Institute For Medical Research Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity

Also Published As

Publication number Publication date
AU6948894A (en) 1994-12-12
EP0702725A4 (en) 1998-09-30
ATE332392T1 (de) 2006-07-15
HUT73213A (en) 1996-06-28
WO1994026923A1 (en) 1994-11-24
DE69434782T2 (de) 2007-06-14
JP3578787B2 (ja) 2004-10-20
HU219807B (hu) 2001-08-28
NO954568D0 (no) 1995-11-13
DE69434782D1 (de) 2006-08-17
EP0702725B1 (en) 2006-07-05
EP0702725A1 (en) 1996-03-27
FI955463A0 (fi) 1995-11-13
KR960702868A (ko) 1996-05-23
CN1126494A (zh) 1996-07-10
FI955463A7 (fi) 1996-01-12
FI955463L (fi) 1996-01-12
HU9503249D0 (en) 1996-01-29
NZ267254A (en) 1997-11-24
JPH0884596A (ja) 1996-04-02
CA2162865A1 (en) 1994-11-24
AU692450B2 (en) 1998-06-11

Similar Documents

Publication Publication Date Title
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
DK0929567T3 (da) Forbedret fastfase-peptidsyntese og middel til anvendelse af en sådan syntese
DE68926303D1 (de) Peptide und antikörper, die die integrin-ligandbindung inhibieren
AU1986588A (en) Growth hormone receptor
CA2224086A1 (en) Conformationally-restricted combinatorial library composition and method
DE68929402D1 (de) Verfahren zur herstellung von wasserlöslichen polypeptiden
NZ238056A (en) Surface protein of metastasis forming tumour cells, related polypeptides, dna encoding these, antibodies, assays and pharmaceuticals
BR9809778A (pt) Polinucleotìdeo isolado, vetor de expressão, peptìdeo ou polipetìdeo isolado, anticorpo, processo para produzir o mesmo, fragmentos de anticorpos, anticorpos de cadeia única ou anticorpos humanizados, e, anticorpo anti-idiotìpico.
WO1997026321A3 (en) Recombinant expression of proteins from secretory cell lines
DK0620854T3 (da) Ekspression og oprensning af rekombinant opløselig vævsfaktor
ES8606494A1 (es) Un metodo de producir un peptido o polipeptido sintetico.
EP0759942A4 (en) INTERLEUKIN-15 RECEPTORS
EP1304381A3 (en) Process for producing hydrophobic polypeptides, proteins or peptides
NO954568L (no) Fremgangsmåte for rekombinant fremstilling av biologisk aktive peptider
DE69333382D1 (de) Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide
GR3023593T3 (en) Protein structure of the plant toxin gelonin
CA2169377A1 (en) Glucoamylase promoter obtained from neurospora crassa and its use in the production of heterologous polypeptides
EP0351804A3 (en) Hcg peptides for use in antibody purification procedures
HUP9801438A3 (en) Recombinant preduodenal lipases and polypeptide derivatives produced by plants, processes for obtaining them and their uses
GR3021095T3 (en) Improved process of purifying recombinant proteins and compounds useful in such process
NZ304789A (en) Genes encoding lymphocyte interferon regulatory factory (lsirf) polypeptides that are transcription factors and specific antibodies to them
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
DE59813388D1 (de) Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 von Cytomegalovirus und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
NZ503852A (en) Death associated kinase containing ankyrin repeats (DAKAR)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application